LGT Group Foundation Has $2.40 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

LGT Group Foundation trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 29,542 shares of the biopharmaceutical company’s stock after selling 2,320 shares during the period. LGT Group Foundation’s holdings in Gilead Sciences were worth $2,397,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Robertson Stephens Wealth Management LLC raised its holdings in Gilead Sciences by 32.4% during the 4th quarter. Robertson Stephens Wealth Management LLC now owns 5,349 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 1,310 shares during the period. McIlrath & Eck LLC raised its holdings in Gilead Sciences by 67.2% during the 4th quarter. McIlrath & Eck LLC now owns 550 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 221 shares during the period. First Trust Direct Indexing L.P. raised its holdings in Gilead Sciences by 23.0% during the 4th quarter. First Trust Direct Indexing L.P. now owns 30,157 shares of the biopharmaceutical company’s stock worth $2,443,000 after buying an additional 5,648 shares during the period. Searle & CO. bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $328,000. Finally, Concord Wealth Partners grew its stake in shares of Gilead Sciences by 34.3% during the 4th quarter. Concord Wealth Partners now owns 18,355 shares of the biopharmaceutical company’s stock worth $1,487,000 after acquiring an additional 4,684 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 0.8 %

GILD stock opened at $64.78 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The company has a fifty day moving average price of $70.72 and a two-hundred day moving average price of $75.94. Gilead Sciences, Inc. has a one year low of $64.33 and a one year high of $87.86. The stock has a market cap of $80.66 billion, a price-to-earnings ratio of 179.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the previous year, the business posted $1.37 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.75%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Analysts Set New Price Targets

GILD has been the subject of several research reports. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. TD Cowen decreased their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Royal Bank of Canada decreased their price target on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research note on Friday, April 26th. Cantor Fitzgerald decreased their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Finally, Maxim Group decreased their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $83.69.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.